NCT06611345 - A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

October 30, 2026

Study Completion Date

March 30, 2027

Conditions

Biliary Tract Cancers (BTC)

Interventions

DEVICE

Tumor Treating Fields

Tumor treating fields will be used each day.

DRUG

Durvalumab

Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.

DRUG

Cisplatin

Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.

Trial Locations (1)

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei